Compare Smurfit WestRock plc Ordinary Shares (SW) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Smurfit WestRock plc Ordinary Shares vs Spyre Therapeutics Inc. Common Stock — how do they compare? Smurfit WestRock plc Ordinary Shares trades at $41.19 (market cap $21.37B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.35B). The key difference: Smurfit WestRock plc Ordinary Shares is far larger — about 2.9× Spyre Therapeutics Inc. Common Stock's market cap, and Smurfit WestRock plc Ordinary Shares pays a 4.44% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Smurfit WestRock plc Ordinary Shares for 5 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| SW | SYRE | |
|---|---|---|
Market Cap | $21.37B | $7.35B |
Volume | 2,776,603 | 1,624,631 |
Sector | Consumer Cyclical | Health |
52-Week High | $51.84 | $108.92 |
52-Week Low | $32.79 | $22.18 |
Typical Hold Time | 5 Days | 0 Days |
Enterprise Value | $34.86B | $6.35B |
Dividend Yield | 4.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Smurfit Westrock (SW) trades at $41.45, showing modest daily gains of 0.93% but facing technical bearish signals with 17 sell indicators versus 4 buys. The company reported three consecutive quarterly earnings misses amid cost pressures, though revenue remains stable above $31 billion. Recent strategic moves include the $420 million acquisition of CMPC's Chilean containerboard business to strengthen regional footprint and reduce costs.
Despite unanimous analyst buy ratings and a $71.50 price target suggesting 72% upside, SW faces execution risks from freight cost inflation and margin compression. The stock's high P/E ratio of 44.01 contrasts with weak profitability metrics (ROE 2.74%), creating a divergence between valuation and fundamental performance that warrants cautious optimism.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Smurfit WestRock plc Ordinary Shares
Smurfit WestRock plc is an Ireland-headquartered packaging company that manufactures corrugated containers and consumer packaging from containerboard and paperboard, operating mills, converting plants, and recycling facilities across more than 40 countries.
Read more on SW →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
